Samuel Kintz, President and CEO: Enliven Therapeutics ELVN Planned sale · Filed 25/03/17

Trade details

Type: Planned sale notice
Stock: Enliven Therapeutics ELVN
Person: Samuel KintzPresident and CEO
Planned sale date: 25/03/17
Filed: 25/03/17

$259.2K to be sold

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 25/02/15~25/04/16

Samuel Kintz's recent trades

Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$2M
75,000 sh
$2M
Filed 02/17
Traded 02/17
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.7M
75,000 sh
$1.7M
Filed 01/09
Traded 01/09
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.3M
82,500 sh
$1.3M
Filed 01/08
Traded 01/08
Samuel KintzPresident and CEO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$84.6K
5,000 sh
$84.6K
Filed 25/12/17
Traded 25/12/17
Samuel KintzPresident and CEO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$272.8K
12,500 sh
$272.8K
Filed 25/11/19
Traded 25/11/17

Samuel Kintz, CEO — plans to sell 12,500 sh of Enliven Therapeutics ELVN · $259.2K · around 03/17 · 10b5-1 plan | Whalegun